Clinical Trial Update: Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder [Phase 2]

View source ↗

Summary

Phase 2 exploratory safety and efficacy trial of EMP-01 for social anxiety disorder has completed. The update summarizes the study purpose, design, and status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Social Anxiety Disorder

Drugs mentioned

• EMP-01

Snippet

Sponsor: atai Therapeutics, Inc. | Conditions: Social Anxiety Disorder | Phase 2 | Status: COMPLETED